PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. While there are positive elements such as revenue growth in specialized loans and strategic partnerships, there are concerns about economic risks and funding reliance. The Q&A section reveals uncertainties around product timelines and management's vague responses, which may dampen investor confidence. The combination of positive and negative factors, along with the lack of market cap data, suggests a neutral stock price movement over the next two weeks.
Key Financial Performance
EsoGuard revenue $1.5 million for Q4 2025, representing a 24% increase over Q3 2025. The increase is attributed to a 29% rise in test volume, which exceeded the target range of 2,500 to 3,000 tests per quarter.
EsoGuard test volume 3,664 tests in Q4 2025, a 29% increase from Q3 2025. This growth is due to solid momentum and operational improvements.
Cash burn rate $1.5 million for Q4 2025. This includes $600,000 for Veris implantable device development, $200,000 in Delaware franchise taxes, and $300,000 in annual compensation expenses.
Equity method investment balance $34 million at the end of 2025, reflecting an $8.5 million year-over-year increase due to a 33% rise in Lucid's stock during 2025.
Veris-related financings $2.3 million in Q1 2025 and $2.5 million in Q2 2025, used to support the development of the Veris implantable device.
GAAP net loss $2.8 million for Q4 2025, including $1 million in noncash charges. The non-GAAP loss was $942,000, primarily due to Veris contractor development costs and Delaware franchise taxes.
Non-GAAP operating expenses Flat over the four quarters following Lucid's deconsolidation in 2024, with Q4 2025 expenses offset by $1.2 million in reimbursements from Lucid for annual compensation expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lucid Diagnostics: Lucid reported Q4 2025 EsoGuard revenue of $1.5 million, with a 29% increase in test volume and 24% revenue growth compared to Q3. Lucid secured a U.S. Department of Veterans Affairs contract, expanding access to 9 million veterans at risk of GERD and esophageal cancer. Positive data from a real-world study of 12,000 patients validated EsoGuard and EsoCheck's performance.
Veris Cancer Care Platform: Veris advanced its cancer care platform with an implantable physiologic monitor, targeting FDA submission in late 2026. Early commercial traction was noted with Ohio State University, including full Epic integration. Veris is expanding its strategic vision to include AI-based tools and clinical decision support services.
Veterans Affairs Contract: Lucid's VA contract expands access to the nation's largest integrated healthcare system, targeting 9 million veterans.
Capital Structure Improvement: PAVmed completed restructuring and recapitalization, removing toxic convertible securities and achieving a clean capital structure.
MedTech Portfolio Relaunch: PAVmed is relaunching its MedTech portfolio, including hiring a new Chief Business Officer and advancing projects like PortIO and a Duke-licensed endoscopic imaging technology.
Strategic Vision for Veris: Veris is transitioning from a remote patient monitoring company to a broader AI-focused entity, developing risk stratification tools and clinical support services.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Financial Risks: The company faces risks related to regulatory approvals, particularly for Veris' implantable physiologic monitor, which is planned for FDA submission later this year. Any delays or issues in obtaining FDA clearance could impact the product's commercial launch and revenue generation. Additionally, the company has undergone significant financial restructuring, including the redemption of convertible debt and reliance on equity and long-term debt financing, which could pose risks if market conditions or investor sentiment change.
Operational and Strategic Execution Risks: The company is relaunching its MedTech portfolio and expanding its strategic vision for Veris, including AI-based tools and clinical decision support services. These initiatives require effective execution and leadership, and any missteps could hinder growth and adoption. The success of these expansions also depends on the ability to secure partnerships and integrate new technologies effectively.
Market and Competitive Risks: Lucid Diagnostics, a key subsidiary, is entering competitive markets with its EsoGuard product and other diagnostic tools. The success of these products depends on market adoption, competitive positioning, and achieving transformative milestones like Medicare coverage. Failure to achieve these could limit revenue growth and market share.
Supply Chain and Development Risks: The development of Veris' implantable device involves reliance on a new vendor for design and manufacturing. Any disruptions or delays in this process could impact the timeline for FDA submission and subsequent commercialization.
Economic and Funding Risks: The company’s operations and expansions are heavily reliant on external funding, including equity and debt financing. Economic uncertainties or changes in investor sentiment could affect the availability of future funding, impacting the company’s ability to execute its strategic plans.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Lucid Diagnostics: Lucid is on the cusp of transformative milestones, including a recent VA contract win and pending Medicare coverage. The company expects to leverage these developments for major value inflection points.
Veris Cancer Care Platform: Veris is advancing its implantable physiologic monitor towards FDA submission planned for later this year. The company is also expanding its strategic vision to include AI-based tools and clinical decision support services, with plans to leverage commercial success at OSU to additional systems and oncology networks.
MedTech Portfolio Relaunch: PAVmed plans to relaunch its MedTech portfolio, including the development of PortIO and a new endoscopic imaging technology licensed from Duke University. The company is actively evaluating additional opportunities to expand its pipeline.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the key metrics being tracked in the commercial relationship with OSU, and is there a timeline for rolling out to other institutions?
A:The key metrics include enrolling a minimum of 1,000 patients within the first year and expanding the platform across various departments. The timeline for broader rollout depends on achieving these goals and securing FDA clearance for the implantable device. The company is focusing its limited capital resources on FDA submission and clearance before broader commercial expansion.
Q:Are there plans to integrate new risk stratification tools into the Veris platform, and how will this affect the current contract with OSU?
A:The development of AI-based risk stratification tools is in early stages and requires extensive data. OSU is partnering in the development of these tools. Once ready, these tools will be integrated into the platform for existing patients. This is part of a broader strategic vision to evolve Veris into a platform offering sophisticated AI-based clinical decision support tools.
Q:What is the status of the new imaging technology licensed from Duke, and what are the plans for its commercialization?
A:The imaging technology is in early development. It combines OSC and a/LCI technologies to detect and differentiate between early and late precancerous conditions in the esophagus. Current efforts focus on redesigning the probe for broader commercial use. After redesign and further clinical testing, the company plans to pursue FDA clearance via a 510(k) pathway and subsequent commercialization.
Q:What areas or products is the company interested in for expanding its medical device portfolio?
A:The company is open to opportunities across various specialties but has a particular interest in technologies related to the GI space, such as gastroesophageal reflux and Barrett's esophagus, due to its existing expertise in these areas. They are also considering opportunities in vascular access and other areas.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines or detailed data for the broader rollout of the Veris platform to other institutions, the development timeline for AI-based tools, and the commercialization timeline for the new imaging technology. Responses were often high-level and lacked precise details or commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
Chief Officer
Duke
Epic
EsoGuard
MedTech portfolio
PAVmed capital
Virgilio
addition
adoption
aspect
cancer
capital structure
center
clinician
company
completion
department OSU
design
development
device
highlight
launch
leader
order
patient
phase engagement
plan step
space
submission FDA
subsidiary
success
system
test
tool
update
vision
work
PAVM Transcript
PAVmed Inc. (PAVM) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call highlights a positive revenue increase and improved net loss, operating expenses, and gross margin, indicating operational improvements. However, the lack of discussion on strategic initiatives, operational updates, or shareholder returns, combined with negative cash flow and forward-looking risks, tempers enthusiasm. The absence of additional insights from the Q&A section further supports a neutral outlook. Without market cap data, the typical small-cap volatility cannot be considered.
PAVmed Inc. (PAVM) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call summary presents a mixed outlook. While there are positive elements such as revenue growth in specialized loans and strategic partnerships, there are concerns about economic risks and funding reliance. The Q&A section reveals uncertainties around product timelines and management's vague responses, which may dampen investor confidence. The combination of positive and negative factors, along with the lack of market cap data, suggests a neutral stock price movement over the next two weeks.
Laurentian Bank of Canada (LB:CA) Q4 2025 Earnings Call Transcript
Unknown12-5
Basic Financial Performance shows mixed results with both positive and negative aspects. Product Development and Business Update lacks clarity, especially regarding the Fairstone transaction. Market Strategy and Expenses indicate a stable but cautious approach. Shareholder Return Plan is stable but restricted in dividend growth. Q&A reveals some concerns over branch closures and unclear future plans. Overall, the sentiment is neutral due to a balance of positive and negative factors, with no significant catalysts for a strong price movement.
PAVmed Inc. (PAVM) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call summary indicates consistent revenue and financial metrics, but there are significant risks due to pending Medicare coverage and regulatory approvals. The Q&A session provided clarity on development timelines and strategies, but did not alleviate concerns about these risks. The equity investment loss and capital raise through a public offering add financial uncertainty. Overall, the sentiment is neutral due to the balance of consistent performance and ongoing risks.
PAVM Slides
PAVM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
